Myelodysplastic Syndrome — Research Summary
Printed from RareWays (rareways.com.au) on 5 April 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Rabdosin B suppresses proliferation of nonsmall cell lung cancer by regulating the SRC/PI3K/AKT signaling pathway.
Chen Xinfei et al. — Pharmaceutical biology (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41858068/
- 2.
Association between red cell distribution width to albumin ratio and all-cause mortality in critically ill patients with myelodysplastic syndrome: a retrospective cohort study.
Huang Zicong et al. — Hematology (Amsterdam, Netherlands) (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41841600/
- 3.
Prognostic impact of myelodysplasia-related gene mutations in ELN-2022 favorable-risk acute myeloid leukemia subtypes.
Zhang Lulu et al. — Annals of medicine (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41797681/
- 4.
Low-dose decitabine increases peripheral NKT-like cell proportions in patients with chronic myeloid neoplasms.
Zhang Zhanqiang et al. — Cancer pathogenesis and therapy (1 July 2026)
https://pubmed.ncbi.nlm.nih.gov/41908667/
- 5.
A complete blood count-based machine learning model for rapid differentiation of aplastic anemia, immune thrombocytopenia, and myelodysplastic syndromes in routine clinical practice.
Wang Xiaohan et al. — Practical laboratory medicine (1 July 2026)
https://pubmed.ncbi.nlm.nih.gov/41867472/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
Recruiting — Phase 3 — Institut de Recherches Internationales Servier
https://clinicaltrials.gov/study/NCT06465953
- 2.
Steps Against the Burden of Parkinson's Disease
Recruiting — Na — The University of New South Wales
https://clinicaltrials.gov/study/NCT07057219
- 3.
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
Recruiting — Phase 3 — Hoffmann-La Roche
https://clinicaltrials.gov/study/NCT07174310
- 4.
Study to Evaluate the Safety and Tolerability of EP0042
Recruiting — Phase 1 — Ellipses Pharma
https://clinicaltrials.gov/study/NCT04581512
- 5.
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Recruiting — Phase 1 — PedAL BCU, LLC
https://clinicaltrials.gov/study/NCT04726241
- 6.
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Recruiting — Phase 3 — Takeda
https://clinicaltrials.gov/study/NCT06499285
- 7.
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Recruiting — Phase 1 — Disc Medicine, Inc
https://clinicaltrials.gov/study/NCT05320198
- 8.
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Recruiting — Phase 3 — Merck Sharp & Dohme LLC
https://clinicaltrials.gov/study/NCT06079879
- 9.
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Recruiting — Alexion Pharmaceuticals, Inc.
https://clinicaltrials.gov/study/NCT06312644
- 10.
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Recruiting — Phase 2 — Takeda
https://clinicaltrials.gov/study/NCT04419649
- 11.
A Study of BGB-11417 in Participants With Myeloid Malignancies
Recruiting — Phase 1 — BeiGene
https://clinicaltrials.gov/study/NCT04771130
- 12.
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Recruiting — Phase 1 — Aptose Biosciences Inc.
https://clinicaltrials.gov/study/NCT03850574
- 13.
Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS
Recruiting — Phase 1 — Clinical Hub for Interventional Research (CHOIR)
https://clinicaltrials.gov/study/NCT05636514
- 14.
A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
Recruiting — Phase 1 — Apollo Therapeutics Ltd
https://clinicaltrials.gov/study/NCT06372717
- 15.
A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Recruiting — Phase 3 — Merck Sharp & Dohme LLC
https://clinicaltrials.gov/study/NCT06351631
- 16.
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
Recruiting — Phase 1 — AstraZeneca
https://clinicaltrials.gov/study/NCT07064122
- 17.
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Recruiting — Phase 1 — Therapeutic Advances in Childhood Leukemia Consortium
https://clinicaltrials.gov/study/NCT05476770
- 18.
A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease
Recruiting — Phase 3 — BlueRock Therapeutics
https://clinicaltrials.gov/study/NCT06944522
- 19.
A Real World Effectiveness Study of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Recruiting — Swedish Orphan Biovitrum
https://clinicaltrials.gov/study/NCT05776472
- 20.
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Recruiting — Phase 3 — Celgene
https://clinicaltrials.gov/study/NCT04064060
- 21.
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Recruiting — Phase 2 — Cogent Biosciences, Inc.
https://clinicaltrials.gov/study/NCT04996875
- 22.
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
Recruiting — Phase 3 — Merck Sharp & Dohme LLC
https://clinicaltrials.gov/study/NCT06456346
- 23.
SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
Recruiting — Phase 1 — Serina Therapeutics
https://clinicaltrials.gov/study/NCT07422675
- 24.
Abbott DBS Post-Market Study of Outcomes for Indications Over Time
Recruiting — Abbott Medical Devices
https://clinicaltrials.gov/study/NCT04071847
- 25.
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Recruiting — Phase 1 — AstraZeneca
https://clinicaltrials.gov/study/NCT07155226
- 26.
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
Recruiting — Phase 1 — Janssen Research & Development, LLC
https://clinicaltrials.gov/study/NCT06651229
- 27.
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Recruiting — Phase 3 — Takeda
https://clinicaltrials.gov/study/NCT07422480
- 28.
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
Recruiting — Phase 3 — Bristol-Myers Squibb
https://clinicaltrials.gov/study/NCT05949684
- 29.
Precision Medicine for Every Child With Cancer
Recruiting — Australian & New Zealand Children's Haematology/Oncology Group
https://clinicaltrials.gov/study/NCT05504772
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Myelodysplastic Syndrome
Myelodysplastic Syndrome encompasses a group of blood cancers in which the bone marrow produces abnormal, dysfunctional blood cells. The condition predominantly affects older adults and can progress to acute myeloid leukaemia. Treatment ranges from supportive care and growth factors to stem cell transplantation in eligible patients.
Most Recent Research
CONTEXT: Rabdosin B (RB), an active compound derived from the Chinese herb Isodon japonicus (Burm. f.) H. Hara, has demonstrated inhibitory effects on non-small cell lung cancer (NSCLC) cell proliferation in prior studies. However, its precise mechanism of action remains unclear. OBJECTIVE: To investigate the mechanism of RB against NSCLC and its synergistic effect with cisplatin (CDDP) via the SRC/PI3K/AKT signaling pathway. MATERIALS AND METHODS: In vitro assays, CCK-8, colony formation, flow cytometry, scratch, Transwell, and Western blot assessed proliferation, apoptosis and migration. Network pharmacology, molecular docking, molecular dynamics simulation (MDS) and cellular thermal shift assay (CETSA) were employed to validate molecular targets. King's formula was used to evaluate the combined effect of RB and CDDP, with xenograft models confirming in vivo efficacy. RESULTS: In vitro, RB significantly suppressed NSCLC proliferation, migration, and invasion while inducing apoptosis. Mechanistically, network pharmacology predicted SRC as a core target. MDS and CETSA subsequently confirmed the direct and stable binding of RB to SRC. Western blot analysis revealed that RB exerted its effect by inhibiting SRC/PI3K/AKT signaling. Notably, RB synergistically enhanced CDDP sensitivity by blocking SRC/PI3K/AKT pathway activation, thereby potentiating apoptosis. Finally, in vivo experiments validated that RB effectively suppressed tumor growth with favorable safety. DISCUSSION AND CONCLUSIONS: RB inhibits NSCLC progression and sensitizes cells to CDDP by directly targeting SRC to inactivate the PI3K/AKT pathway. These findings identify a novel mechanism of RB against NSCLC and suggest its potential as a therapeutic strategy.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.